Despite clinical settings being currently limited to phase I/II human trials, preclinical studies on HER-2-loaded and cyclin D1-loaded dendritic cell vaccines have been shown to significantly inhibit the HBC xenografted tumor growth in mice (323). The gene discussed is ERBB2; the disease is neoplasm.